To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)

Phase 2

Completed

• Conditions: Obesity

• Registration Number: NCT00482196
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

To study different doses of MK0493 for safety, efficacy and tolerability in obese patients.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2005-07
• Primary Completion: 2006-03
• Study Completion: 2006-03
• Study First Submitted: 2007-06-01
• Study First Submitted QC: 2007-06-01
• Study First Posted: 2007-06-05
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-27
• Last Update Posted: 2015-04-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 173

Inclusion Criteria

• Patient is between 21 and 65 years of age

Read More

Exclusion Criteria

• HIV positive as determined by medical history
• Patient is pregnant, lactating or plans to become pregnant
• Patient has undergone surgical treatment for obesity
• Patient has undergone a surgical procedure within 4 weeks prior to Visit 1 or plans to undergo a surgical procedure during the study
• Patient plans to consume more than 2 glasses of grapefruit juice per day during the study
• Patient has participated in another clinical study (involving an investigational drug) within 3 months prior to restudy screening

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL